SCHEMBL1841951

SCHEMBL1841951

CCOC(=O)c1cc(Cl)nc(Cl)c1N

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ACHE P22303 4/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
IKBKB O14920 1/20 0.44
TSHR P16473 2/20 0.44
CASP1 P29466 1/20 0.44
ALOX15 P16050 1/20 0.43
HSP90AA1 P07900 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29522769 1.00 KDM4E (0.47) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL22902580 0.88 IKBKB (0.53) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL17840873 0.85 KDM4E (0.44) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL30641332 0.85 KDM4E (0.44) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL1579279 0.84 ALDH1A1 (0.47) KDM4EHSD17B10ALDH1A1MAPK1TSHR
SCHEMBL30416311 0.84 ALDH1A1 (0.47) KDM4EHSD17B10ALDH1A1MAPK1TSHR
SCHEMBL29678780 0.82 KDM4E (0.53) KDM4EHSD17B10ALDH1A1ACHEGAA
SCHEMBL110643 0.82 KDM4E (0.53) KDM4EHSD17B10ALDH1A1ACHEGAA
SCHEMBL1578944 0.79 CYP4F2 (0.50) KDM4EALDH1A1MAPK1TSHRCASP1
SCHEMBL31138796 0.79 CYP4F2 (0.50) KDM4EALDH1A1MAPK1TSHRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114423757-B Tricyclic heteroaryl compounds useful as IRAK4 inhibitors 百时美施贵宝公司 2024-07-02 CN disclosed
EP-3999508-B1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-30 EP disclosed
EP-3999508-B1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-30 EP disclosed
CN-114423757-A Tricyclic heteroaryl compounds useful as IRAK4 inhibitors 百时美施贵宝公司 2022-04-29 CN disclosed
WO-2021011724-A1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-01-21 WO disclosed
EP-1373210-B1 HETEROCYCLIC DIAMIDE INVERTEBRATE PEST CONTROL AGENTS DU PONT (US) 2011-05-18 EP disclosed
US-7560564-B2 Heterocyclic diamide invertebrate pest control agents E.I. DU PONT DE NEMOURS AND COMPANY (US) 2009-07-14 US disclosed
US-20060205748-A1 Heterocyclic diamide invertebrate pest control agents ANNIS GARY D 2006-09-14 US disclosed
US-20040102324-A1 Heterocyclic diamide invertebrate pest control agents E.I. DU PONT DE NEMOURS AND COMPANY 2004-05-27 US disclosed
EP-1373210-A1 HETEROCYCLIC DIAMIDE INVERTEBRATE PEST CONTROL AGENTS E. I. du Pont de Nemours and Company (US) 2004-01-02 EP disclosed
WO-2002070483-A1 HETEROCYCLIC DIAMIDE INVERTEBRATE PEST CONTROL AGENTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205748-A1 Heterocyclic diamide invertebrate pest control agents DDT, DBF4, C1S KDM4E 1378/4885HSD17B10 3110/4885ALDH1A1 2826/4885
US-20040102324-A1 Heterocyclic diamide invertebrate pest control agents DDT, DBF4, DDC KDM4E 835/4885HSD17B10 3238/4885ALDH1A1 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.